2023
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer
Fernandez A, Robbins C, Gaule P, Agostini-Vulaj D, Anders R, Bellizzi A, Chen W, Chen Z, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan Y, Weidler J, Bates M, Zhang X, Rimm D. Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer. Modern Pathology 2023, 36: 100128. PMID: 36889057, PMCID: PMC10198879, DOI: 10.1016/j.modpat.2023.100128.Peer-Reviewed Original ResearchConceptsOverall percent agreementCut pointsReal-world settingHigher cut pointsCell death ligand 1Percent agreementGastroesophageal junction cancerPD-L1 immunohistochemistryDeath ligand 1Companion diagnostic testsMessenger RNA measurementsJunction cancerCancer casesImmunohistochemistry assaysIHC resultsDrug AdministrationPredictive valueScoring systemRange of assaysDiagnostic testsInstitutional studyRNA measurementsImmunohistochemistryPoor specificityPathologist's reading
2020
Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease
Irshaid L, Robert ME, Zhang X. Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Archives Of Pathology & Laboratory Medicine 2020, 145: 191-200. PMID: 33501492, DOI: 10.5858/arpa.2019-0700-oa.Peer-Reviewed Original ResearchConceptsHelicobacter pylori gastritisUpper gastrointestinal tractCeliac diseasePylori gastritisCPI therapyCD8 ratioDuodenal biopsiesInflammatory changesLymphoid aggregatesGastrointestinal tractAnti-programmed death receptor-1/Anti-cytotoxic T-lymphocyteDeath receptor-1/Immune checkpoint inhibitor therapyImmune-related adverse eventsDeath ligand 1 antibodyColonic mucosal changesGastrointestinal tract inflammationLamina propria CD3Lamina propria inflammationUpper gastrointestinal biopsiesUpper gastrointestinal injuryCheckpoint inhibitor therapyH pylori gastritisCD8 T cells